GBA Presents: House of Gummy-!

Discussion in 'Stocks' started by stonedinvestor, May 13, 2023.

  1. Nine_Ender

    Nine_Ender

    I sometimes day trade CPG on decent Oil days or if the price drops enough in the range. It's not one of my main plays in Oil because it has serious resistance at $10 Cdn and not as much torque at the moment as some of their peers. It is a very cheap stock but until they get some respect on the market I'm not fighting it beyond easy momentum moves. I did play it late week but would have been better off keeping my Crew Energy ( nat gas ) one of my favorite trading stocks. I think the dual listing in NY actually hurts CPG at times more then it helps. However, in the scenario where Oil stays high and they bust out a good quarter, the stock could break resistance and run pretty good because it's a low P/E stock that tends to boost dividends ( some of the fund managers like it ).

    Some Cdn Nat Gas companies had really, really good numbers even with the huge drop in prices. I had heard they are highly profitable even at $1.50 nat gas but the market seemed to be surprised by the profits ( eg Arc Resources, Crew Energy, maybe Pipestone ).
     
    Last edited: May 21, 2023
    #461     May 21, 2023
  2. 1980 or 81?
     
    #462     May 21, 2023
  3. vanzandt

    vanzandt

    I think we may get something this week.
    g/l on this one Stoney. :thumbsup:
     
    #463     May 21, 2023
  4. Goooooooooooood Monday Morn-

    --Dice Therapeutics initiated with Buy, $71 target at Canaccord 07:04 DICE :wtf:

    ruh roe, I've been dragging my feet.....
     
    #464     May 22, 2023
  5. Vz we did it-!

    NuScale Power Corporation (SMR)
    NYSE - NYSE
    7.69-0.10(-1.28%)
    At close: 04:00PM EDT
    8.17+0.48(+6.24%)<---------- Vz is back! :)
    Pre-Market:07:24AM EDT

    CI&T valuation attractive after 'solid beat,' says Citi 05:47 CINT

    Nuscale Power's VOYGR reactor to be deployed by Biden administration » 06:54 SMR

    SentinelOne price target raised to $22 from $17 at Barclays » 05:30 S

    Hovde starts Zions at Outperform, says 'firing on all cylinders' » 06:53 ZION

    Block deserves more credit for its execution, says Mizuho » 06:37 SQ

    Flutter Entertainment upgraded to Buy from Neutral at Redburn 05:17 PDYPY
     
    #465     May 22, 2023
    vanzandt likes this.
  6. The people they be dying--
    RIP Andy Rourke-


    You guys were such an important part of my life--Thank You. ~stoney
     
    #466     May 22, 2023
  7. BAC-- says 4,300<--- change in tone!!! BIG

    With the Micron news today and earn coming up on NVDA be very careful with tech...part of that BAC market upgrade was a lean towards cyclical plays,,,

    I see a shift coming. Apple can be shorted.

    Apple drops 1% to $173.44 after Loop downgrades on guidance risk 07:20 AAPL
     
    #467     May 22, 2023


  8. I think you are right on target.. about three years after this...

     
    #468     May 22, 2023
    TrailerParkTed likes this.
  9. Outlook Therapeutics, Inc. (OTLK) $1.00-----> $1.40
    NasdaqCM - NasdaqCM Real Time Price.
    1.3400+0.1200 (+9.84%)<---------:caution:
    At close: May 19 04:00PM EDT
    1.4000 +0.06 (+4.48%)<---------:caution:
    Pre-Market: 07:15AM EDT
     
    #469     May 22, 2023
  10. [​IMG]
    Growth Investors: Industry Analysts Just Upgraded Their Aemetis, Inc. (NASDAQ:AMTX) Revenue Forecasts By 12%

    In this article:
    AMTX
    +31.97%


    Aemetis, Inc. (NASDAQ:AMTX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The analysts have sharply increased their revenue numbers, with a view that Aemetis will make substantially more sales than they'd previously expected. Investors have been pretty optimistic on Aemetis too, with the stock up 80% to US$3.22 over the past week. We'll be curious to see if these new estimates convince the market to lift the stock price higher still.

    Following the upgrade, the latest consensus from Aemetis' six analysts is for revenues of US$298m in 2023, which would reflect a major 44% improvement in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$265m in 2023. It looks like there's been a clear increase in optimism around Aemetis, given the nice increase in revenue forecasts.



    [​IMG]
    earnings-and-revenue-growth
    We'd point out that there was no major changes to their price target of US$11.05, suggesting the latest estimates were not enough to shift their view on the value of the business.
     
    #470     May 22, 2023